For example, the presence of EGFR mutations in NSCLC predicts response to EGFR tyrosine kinase inhibitors.301 Biomarker-driven therapy selection remains an area of intense research and is critical for the realization of personalized medicine. Here, EGFR is linked to non-small cell lung carcinoma.